Localized scleroderma, as the term denotes, is localized to the skin on the hands and face. It is characterized by slow progression and rarely transforms to the systemic type. Localized scleroderma is ...

Fibrocell Science has submitted an Investigational New Drug Application (IND) with the FDA for a gene therapy candidate to treat moderate to severe localized scleroderma. Fibrocell Science has ...

Localized scleroderma is a rare connective tissue disorder characterized by hardening and thickening of the skin due to increased collagen density. A quarter of patients affected also experience ...

Clinical enrollment for an open-label, single-arm Phase 1/2 trial of FCX-013 was initiated in August 2018. Fibrocell Science announced that the Food and Drug Administration (FDA) has granted Fast ...

Scleroderma is a rare and often fatal disease, causing the thickening of tissue, that currently lacks a cure and any effective treatments. A group of researchers is looking to change that. The group ...

Disclosure: Kevin Deane, MD, has disclosed the following relevant financial relationships: Receiving grant funding from: NIH for the study of genetic and environmental factors that may influence the ...

Fibrocell Science, a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, announced the submission of an Investigational New Drug ...

Scleroderma, also known as systemic sclerosis, is a group of rare diseases that involve the hardening and tightening of the skin. It also may cause problems in the blood vessels, internal organs and ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...